DNase I aggravates islet β-cell apoptosis in type 2 diabetes

Zhu,Bin; Zhang,Lei; Zhang,Yue-Ying; Wang,Lei; Li,Xin‑Gang; Liu,Teng; Fu,Yu‑Ke; Zheng,Yan‑Fei; Li,Ping; Zhao,Zhi‑Gang

doi:10.3892/mmr.2016.5102

DNase I aggravates islet β-cell apoptosis in type 2 diabetes

Authors:
- Bin Zhu
- Lei Zhang
- Yue-Ying Zhang
- Lei Wang
- Xin‑Gang Li
- Teng Liu
- Yu‑Ke Fu
- Yan‑Fei Zheng
- Ping Li
- Zhi‑Gang Zhao
View Affiliations

Affiliations: Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China, Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, P.R. China, Department of Chinese Medicine, Beijing Hepingli Hospital, Beijing 100013, P.R. China, Department of Chinese Medicine, The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing 100050, P.R. China, Department of Nephrology, China‑Japan Friendship Hospital, Beijing 100029, P.R. China
Published online on: April 11, 2016 https://doi.org/10.3892/mmr.2016.5102
Pages: 4577-4584
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Deoxyribonuclease I (DNase I) is an endonuclease responsible for the destruction of chromatin during apoptosis. However, its role in diabetes remains unclear. The aim of the current study was to investigate the role of DNase I combined with high glucose levels in β‑cell apoptosis. Human samples were collected and the DNase I activity was examined. High glucose‑cultured INS‑1 cells were transfected with DNase I small interfering RNA (siRNA) and the cell apoptosis was examined by western blotting and flow cytometry. Cell viability was analyzed by the Cell Counting Kit‑8 assay. Cell apoptosis resulting from 50 mU/µl DNase I was also observed by flow cytometry, terminal deoxynucleotidyl transferase dUTP nick‑end labeling stain and western blotting. Compared with healthy controls, the serum DNase I activity of patients with diabetes was significantly increased (P<0.05). In addition, DNase I expression was observed to be significantly increased in human pancreatic tissues. The addition of high glucose upregulated the cell apoptotic rate, whereas DNase I knockdown significantly reduced apoptosis in cells treated with high glucose. In addition, the western blotting results indicated that caspase‑3 was increased subsequent to treatment of cells with 30 mM high glucose, however, this increase can be reversed by transfection with DNase I siRNA (P<0.05). Compared with cells cultured in normal conditions and high glucose, 50 mU/µl DNase I was able to significantly increase the cell apoptotic rate and level of caspase-3. DNase I activity was observed to be increased in type 2 diabetes, and high glucose combined with increased DNase I is suggested to aggravate β-cell apoptosis.

View Figures

View References

1	Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA and Butler PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 52:102–110. 2003. View Article : Google Scholar
2	Mandrup-Poulsen T: Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol. 66:1433–1440. 2003. View Article : Google Scholar : PubMed/NCBI
3	Ardestani A, Paroni F, Azizi Z, Kaur S, Khobragade V, Yuan T, Frogne T, Tao W, Oberholzer J, Pattou F, et al: MST1 is a key regulator of beta cell apoptosis and dysfunction in diabetes. Nat Med. 20:385–397. 2014. View Article : Google Scholar : PubMed/NCBI
4	Zhou Z, Zhu C, Ren J and Dong S: A graphene-based real-time fluorescent assay of deoxyribonuclease I activity and inhibition. Anal Chim Acta. 740:88–92. 2012. View Article : Google Scholar : PubMed/NCBI
5	Kaneko Y, Takeshita H, Mogi K, Nakajima T, Yasuda T, Itoi M, Kuwano H and Kishi K: Molecular, biochemical and immunological analyses of canine pancreatic DNase I. J Biochem. 134:711–718. 2003. View Article : Google Scholar : PubMed/NCBI
6	Funakoshi A, Wakasugi H and Ibayashi H: Clinical investigation of serum deoxyribonuclease: II. Clinical studies of serum deoxyribonuclease activity in pancreatic disease. Gastroenterol Jpn. 14:436–440. 1979.PubMed/NCBI
7	Martinez-Valle F, Balada E, Ordi-Ros J, Bujan-Rivas S, Sellas-Fernandez A and Vilardell-Tarres M: DNase 1 activity in patients with systemic lupus erythematosus: Relationship with epidemiological, clinical, immunological and therapeutical features. Lupus. 18:418–423. 2009. View Article : Google Scholar : PubMed/NCBI
8	Kuribara J, Tada H, Kawai Y, Kawaguchi R, Hoshizaki H, Arakawa K, Kitayama M, Kajinami K, Kurabayashi M, Oshima S, et al: Levels of serum deoxyribonuclease I activity on admission in patients with acute myocardial infarction can be useful in predicting left ventricular enlargement due to remodeling. J Cardiol. 53:196–203. 2009. View Article : Google Scholar : PubMed/NCBI
9	St-Onge L, Wehr R and Gruss P: Pancreas development and diabetes. Curr Opin Genet Dev. 9:295–300. 1999. View Article : Google Scholar : PubMed/NCBI
10	Zhu B, Gong Y, Chen P, Zhang H, Zhao T and Li P: Increased DNase I activity in diabetes might be associated with injury of pancreas. Mol Cell Biochem. 393:23–32. 2014. View Article : Google Scholar : PubMed/NCBI
11	Tinazzi E, Puccetti A, Gerli R, Rigo A, Migliorini P, Simeoni S, Beri R, Dolcino M, Martinelli N, Corrocher R and Lunardi C: Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: A possible explanation for the lack of efficacy of hrDNase I treatment. Int Immunol. 21:237–243. 2009. View Article : Google Scholar : PubMed/NCBI
12	Errami Y, Naura AS, Kim H, Ju J, Suzuki Y, El-Bahrawy AH, Ghonim MA, Hemeida RA, Mansy MS, Zhang J, et al: Apoptotic DNA fragmentation may be a cooperative activity between caspase-activated deoxyribonuclease and the poly(ADP-ribose) polymerase-regulated DNAS1L3, an endoplasm ic reticulum-localized endonuclease that translocates to the nucleus during apoptosis. J Biol Chem. 288:3460–3468. 2013. View Article : Google Scholar :
13	Shiokawa D and Tanuma S: Characterization of human DNase I family endonucleases and activation of DNase gamma during apoptosis. Biochemistry. 40:143–152. 2001. View Article : Google Scholar : PubMed/NCBI
14	Rosner K, Kasprzak MF, Horenstein AC, Thurston HL, Abrams J, Kerwin LY, Mehregan DA and Mehregan DR: Engineering a waste management enzyme to overcome cancer resistance to apoptosis: Adding DNase1 to the anti-cancer toolbox. Cancer Gene Ther. 18:346–357. 2011. View Article : Google Scholar : PubMed/NCBI
15	Oliveri M, Daga A, Cantoni C, Lunardi C, Millo R and Puccetti A: DNase I mediates internucleosomal DNA degradation in human cells undergoing drug-induced apoptosis. Eur J Immunol. 31:743–751. 2001. View Article : Google Scholar : PubMed/NCBI
16	Hall AK: Molecular interactions between G-actin, DNase I and the beta-thymosins in apoptosis: A hypothesis. Med Hypotheses. 43:125–131. 1994. View Article : Google Scholar : PubMed/NCBI
17	Martínez Valle F, Balada E, Ordi-Ros J and Vilardell-Tarres M: DNase 1 and systemic lupus erythematosus. Autoimmun Rev. 7:359–363. 2008. View Article : Google Scholar : PubMed/NCBI
18	Martinez-Valle F, Balada E, Ordi-Ros J, Bujan-Rivas S, Sellas-Fernandez A and Vilardell-Tarres M: DNase1 activity in systemic lupus erythematosus patients with and without nephropathy. Rheumatol Int. 30:1601–1604. 2010. View Article : Google Scholar
19	Fujibayashi K, Kawai Y, Kitayama M, Akao H, Ishida R, Motoyama A, Wakasa M, Arakawa K, Ueki M, Kajinami K and Yasuda T: Serum deoxyribonuclease I activity can be a useful diagnostic marker for the early diagnosis of unstable angina pectoris or non-ST-segment elevation myocardial infarction. J Cardiol. 59:258–265. 2012. View Article : Google Scholar : PubMed/NCBI
20	Yasuda T, Iida R, Kawai Y, Nakajima T, Kominato Y, Fujihara J and Takeshita H: Serum deoxyribonuclease I can be used as a useful marker for diagnosis of death due to ischemic heart disease. Leg Med (Tokyo). 11(Suppl 1): S213–S215. 2009. View Article : Google Scholar
21	Boyle AP, Davis S, Shulha HP, Meltzer P, Margulies EH, Weng Z, Furey TS and Crawford GE: High-resolution mapping and characterization of open chromatin across the genome. Cell. 132:311–322. 2008. View Article : Google Scholar : PubMed/NCBI
22	Thurman RE, Rynes E, Humbert R, Vierstra J, Maurano MT, Haugen E, Sheffield NC, Stergachis AB, Wang H, Vernot B, et al: The accessible chromatin landscape of the human genome. Nature. 489:75–82. 2012. View Article : Google Scholar : PubMed/NCBI
23	Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, Reynolds AP, Sandstrom R, Qu H, Brody J, et al: Systematic localization of common disease-associated variation in regulatory DNA. Science. 337:1190–1195. 2012. View Article : Google Scholar : PubMed/NCBI
24	Stitzel ML, Sethupathy P, Pearson DS, Chines PS, Song L, Erdos MR, Welch R, Parker SC, Boyle AP, Scott LJ, et al: Global epigenomic analysis of primary human pancreatic islets provides insights into type 2 diabetes susceptibility loci. Cell Metab. 12:443–455. 2010. View Article : Google Scholar : PubMed/NCBI